Description
Elacestrant is an investigational medication currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer. It is being evaluated, often in combination with other drugs like BGB-43395 or Fulvestrant, particularly in patients whose tumors have a specific genetic change called a HER2 mutation. Clinical trials are ongoing to determine if Elacestrant is safe and effective for these patients. It is currently in Phase 1 trials for colorectal cancer, meaning it is being tested for the first time in humans to assess safety and determine the best way to give it.
Mechanism of Action
Elacestrant is designed to target a specific protein involved in the growth and spread of certain cancer cells. It works by blocking the activity of this protein, which may help slow down or stop the growth of tumors that rely on this protein's signaling pathway. The specific protein targeted by Elacestrant is being characterized in clinical trials, particularly in tumors with HER2 mutations.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.